UY35333A - Compuestos de azabencimidazol - Google Patents

Compuestos de azabencimidazol

Info

Publication number
UY35333A
UY35333A UY0001035333A UY35333A UY35333A UY 35333 A UY35333 A UY 35333A UY 0001035333 A UY0001035333 A UY 0001035333A UY 35333 A UY35333 A UY 35333A UY 35333 A UY35333 A UY 35333A
Authority
UY
Uruguay
Prior art keywords
compounds
azabencimidazol
substituents
formula
pharmaceutically acceptable
Prior art date
Application number
UY0001035333A
Other languages
English (en)
Inventor
Hayward Matthew Merrill
Verhoest Patrick Robert
Patel Nandini Chaturbhai
Chappie Thomas Allen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50151342&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY35333(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of UY35333A publication Critical patent/UY35333A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

La presente invención se refiere a compuestos de la Fórmula I: o una sal de aquellos aceptable desde el punto de vista farmacéutico, en donde los sustituyentes son como se definen en la presente.
UY0001035333A 2013-02-19 2014-02-18 Compuestos de azabencimidazol UY35333A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361766268P 2013-02-19 2013-02-19

Publications (1)

Publication Number Publication Date
UY35333A true UY35333A (es) 2014-09-30

Family

ID=50151342

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035333A UY35333A (es) 2013-02-19 2014-02-18 Compuestos de azabencimidazol

Country Status (30)

Country Link
US (2) US9120788B2 (es)
EP (1) EP2958915B1 (es)
JP (2) JP6505023B2 (es)
KR (1) KR20150119370A (es)
CN (1) CN105121439A (es)
AP (1) AP2015008663A0 (es)
AR (1) AR094702A1 (es)
AU (1) AU2014220351A1 (es)
BR (1) BR112015019276A2 (es)
CA (1) CA2900302C (es)
CL (1) CL2015002222A1 (es)
CR (1) CR20150425A (es)
CU (1) CU20150082A7 (es)
DO (1) DOP2015000201A (es)
EA (1) EA201591360A1 (es)
EC (1) ECSP15035278A (es)
ES (1) ES2638850T3 (es)
HK (1) HK1217945A1 (es)
IL (1) IL240672A0 (es)
MA (1) MA38333A1 (es)
MD (1) MD20150071A2 (es)
MX (1) MX2015010714A (es)
NI (1) NI201500112A (es)
PE (1) PE20151332A1 (es)
PH (1) PH12015501755A1 (es)
SG (1) SG11201505878UA (es)
TN (1) TN2015000347A1 (es)
TW (1) TW201443048A (es)
UY (1) UY35333A (es)
WO (1) WO2014128585A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20151332A1 (es) 2013-02-19 2015-09-20 Pfizer Compuestos de azabencimidazol
JP6713982B2 (ja) 2014-07-24 2020-06-24 ファイザー・インク ピラゾロピリミジン化合物
KR102061952B1 (ko) 2014-08-06 2020-01-02 화이자 인코포레이티드 이미다조피리다진 화합물
HUE053943T2 (hu) * 2015-04-29 2021-08-30 Janssen Pharmaceutica Nv Azabenzimidazolok és ampa receptor modulátorokként való alkalmazásuk
US10611730B2 (en) 2015-04-29 2020-04-07 Janssen Pharmaceutica Nv Benzimidazolone and benzothiazolone compounds and their use as AMPA receptor modulators
CN107750250B (zh) 2015-04-29 2021-09-07 詹森药业有限公司 吲哚酮化合物及其作为ampa受体调节剂的用途
NZ736055A (en) 2015-04-29 2023-05-26 Janssen Pharmaceutica Nv Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
CA2989456C (en) * 2015-06-17 2022-01-04 Pfizer Inc. Tricyclic compounds and their use as phosphodiesterase inhibitors
AR107099A1 (es) * 2015-12-22 2018-03-21 Gruenenthal Gmbh Compuestos espiro-[indolin heterocicloalcano] como inhibidores de la fosfodiesterasa
RU2719599C2 (ru) * 2016-02-23 2020-04-21 Пфайзер Инк. Соединения 6, 7-дигидро-5H-пиразоло[5,1-b][1,3]оксазин-2-карбоксамида
CN109563051A (zh) * 2016-08-22 2019-04-02 南京明德新药研发股份有限公司 作为pde4抑制剂的并环类化合物
WO2018234354A1 (en) 2017-06-20 2018-12-27 Grünenthal GmbH NOVEL SUBSTITUTED 3-INDOLE AND 3-INDAZOLE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS
WO2018234353A1 (en) 2017-06-20 2018-12-27 Grünenthal GmbH NOVEL SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE
EP3643711A1 (en) 2018-10-24 2020-04-29 Bayer Animal Health GmbH New anthelmintic compounds
US20230148589A1 (en) * 2020-03-31 2023-05-18 Lg Chem, Ltd. Composition for protecting islet transplantation
CN112390750B (zh) * 2020-11-11 2022-03-01 常州大学 作为选择性磷酸二酯酶2抑制剂的喹啉酮类化合物及其制备方法

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814651A (en) 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
EP0683234B2 (en) 1993-01-25 2007-06-06 Takeda Chemical Industries, Ltd. Antibody against beta-amyloid or their derivative and use thereof
JPH08295667A (ja) * 1995-04-27 1996-11-12 Takeda Chem Ind Ltd 複素環化合物、その製造法および剤
JPH08295687A (ja) * 1995-04-28 1996-11-12 Ube Ind Ltd 無水シトラコン酸の製造法
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
WO1998044955A1 (en) 1997-04-09 1998-10-15 Mindset Ltd. Recombinant antibodies specific for beta-amyloid ends, dna encoding and methods of use thereof
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
JP2004509059A (ja) * 1999-06-03 2004-03-25 アボット・ラボラトリーズ 細胞接着抑制性抗炎症化合物
HUP0201723A3 (en) 1999-06-28 2004-04-28 Janssen Pharmaceutica Nv Respiratory syncytial virus replication inhibitors
AU3540101A (en) 2000-01-07 2001-07-16 Universitaire Instelling Antwerpen Purine derivatives, process for their preparation and use thereof
CZ306683B6 (cs) 2000-02-24 2017-05-03 Washington University Léčivo pro prevenci nebo léčení preklinické nebo klinické Alzheimerovy nemoci
CN1173975C (zh) 2000-04-27 2004-11-03 山之内制药株式会社 咪唑并吡啶衍生物
DE10045112A1 (de) 2000-09-11 2002-03-21 Merck Patent Gmbh Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems
EP1335738A4 (en) 2000-11-03 2004-09-08 Proteotech Inc METHODS OF ISOLATING AMYLOID INHIBITOR COMPOUNDS AND USE OF COMPOUNDS USED FROM UNCARIA TOMENTOSA AND PARENT PLANTS
GB0115181D0 (en) 2001-06-20 2001-08-15 Glaxo Group Ltd Novel use
WO2003000697A1 (fr) 2001-06-22 2003-01-03 Takeda Chemical Industries, Ltd. Derive de furo-isoquinoline, procede de production de ce compose et utilisation de ce compose
ATE296630T1 (de) 2001-06-27 2005-06-15 Merck Frosst Canada Inc Substituierte 8-arylchinoline als pde4-hemmer
KR20040017246A (ko) 2001-06-29 2004-02-26 니켄 가가쿠 가부시키가이샤 사이클로알케논 유도체
WO2003008396A1 (fr) 2001-07-16 2003-01-30 Nikken Chemicals Co., Ltd. Derive d'oxazine actif sur le plan optique
RU2004104945A (ru) 2001-07-18 2005-07-10 Мерк Патент ГмбХ (DE) Производные 4-(бензилиденамино)-3-(метилсульфанил)-4h-1,2,4-триазин-5-она, обладающие ингибирующим действием по отношению к фосфодиэстеразе iv и антагонистичным действием по отношению к tnf, для лечения сердечных заболеваний и аллергии
WO2003008373A1 (de) 2001-07-19 2003-01-30 Merck Patent Gmbh Tyrosinhydrazide
FR2827599A1 (fr) 2001-07-20 2003-01-24 Neuro3D Composes derives de quinoleine et quinoxaline,preparation et utilisations
GB0118373D0 (en) 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
TWI221838B (en) 2001-08-09 2004-10-11 Tanabe Seiyaku Co Pyrazinoisoquinoline compound or naphthalene compound
EP1285922A1 (en) 2001-08-13 2003-02-26 Warner-Lambert Company 1-Alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors
FR2828693B1 (fr) 2001-08-14 2004-06-18 Exonhit Therapeutics Sa Nouvelle cible moleculaire de la neurotoxicite
WO2003015785A1 (en) 2001-08-15 2003-02-27 Icos Corporation 2h-phthalazin-1-ones and methods for use thereof
AU2002333193A1 (en) 2001-08-15 2003-03-03 Leo Pharma A/S A pharmaceutical composition for dermal application
US20040192898A1 (en) 2001-08-17 2004-09-30 Jia Audrey Yunhua Anti-abeta antibodies
JO2311B1 (en) 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
GB0122031D0 (en) 2001-09-12 2001-10-31 Pfizer Ltd Use of pde4 inhibitors in a dry powder inhaler
ATE349243T1 (de) 2001-09-19 2007-01-15 Altana Pharma Ag Kombination von einem pde-hemmer und eines leukotrien rezeptor antagonisten
PT1429807E (pt) 2001-09-19 2007-05-31 Altana Pharma Ag Combinação de um nsaid e de um inibidor de pde-4
WO2003035650A1 (fr) 2001-09-25 2003-05-01 Takeda Chemical Industries, Ltd. Inhibiteur d'entree
CA2462453C (en) 2001-10-02 2009-07-28 Pharmacia & Upjohn Company Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
GB0123951D0 (en) 2001-10-05 2001-11-28 Glaxo Group Ltd Therapies for treating respiratory diseases
DE10150517A1 (de) 2001-10-12 2003-04-17 Merck Patent Gmbh Verwendung von Phosphodiesterase IV-Inhibitoren
RU2340600C2 (ru) 2001-10-16 2008-12-10 Мемори Фармасьютиклз Корпорейшн Производные 4-(4-алкокси-3-гидроксифенил)-2-пирролидона в качестве ингибиторов pde-4 для лечения неврологических синдромов
US7241890B2 (en) 2001-10-30 2007-07-10 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
JP2005515975A (ja) 2001-10-31 2005-06-02 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング ４型ホスホジエステラーゼ阻害剤およびこれらの使用
EP1506196B1 (en) 2001-11-01 2012-01-18 Icagen, Inc. Pyrazolopyrimidines as sodium channel inhibitors
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
AR037517A1 (es) 2001-11-05 2004-11-17 Novartis Ag Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
PL369738A1 (en) 2001-11-05 2005-05-02 Merck Patent Gmbh Hydrazono-malonitriles
US20030092706A1 (en) 2001-11-09 2003-05-15 Johannes Barsig Combination
IS7221A (is) 2001-11-15 2004-04-15 Memory Pharmaceuticals Corporation Hringlaga adenosínmónófosfat fosfódíesterasa 4D7 ísóform og aðferðir til notkunar þeirra
FR2832711B1 (fr) 2001-11-26 2004-01-30 Warner Lambert Co Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation
US20050101000A1 (en) 2002-12-11 2005-05-12 Isis Pharmaceuticals Inc. Modulation of phosphodiesterase 4B expression
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
US20040146512A1 (en) 2002-10-09 2004-07-29 Arnon Rosenthal Methods of treating Alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
AU2003283303A1 (en) 2002-11-08 2004-06-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4b (pde4b)
WO2004052315A2 (en) 2002-12-11 2004-06-24 Merck & Co., Inc. Tyrosine kinase inhibitors
JP2006522749A (ja) 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ 置換ピラゾロ［１，５−ａ］ピリミジンの薬学的使用
DK1615647T3 (da) 2003-04-11 2010-04-06 High Point Pharmaceuticals Llc Farmaceutisk anvendelse af kondenserede 1,2,4-triazoler
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
US7741341B2 (en) 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
EP1638935A1 (en) 2003-06-19 2006-03-29 Pfizer Products Inc. Nk1 antagonist
AU2004253543B2 (en) 2003-07-01 2009-02-19 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
FR2857966A1 (fr) 2003-07-24 2005-01-28 Aventis Pharma Sa Produits aryl-heteroaromatiques, compositions les contenant et utilisation
US20050020587A1 (en) 2003-07-25 2005-01-27 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
CA2538220A1 (en) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited Use of antibody
GB0322722D0 (en) 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
GB0322726D0 (en) 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
CA2539752A1 (en) 2003-09-29 2005-04-07 Topigen Pharmaceutique Inc. Oligonucleotide compositions and methods for treating disease including inflammatory conditions
GB0327319D0 (en) 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
US20050137234A1 (en) 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
BRPI0507374A (pt) 2004-02-02 2007-07-10 Pfizer Prod Inc moduladores do receptor de histamina-3
JP2008503446A (ja) 2004-05-06 2008-02-07 プレキシコン，インコーポレーテッド Ｐｄｅ４ｂ阻害剤及びその使用
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
US7807165B2 (en) 2004-07-30 2010-10-05 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
CA2583428A1 (en) 2004-09-03 2006-03-09 Plexxikon, Inc. Bicyclic heteroaryl pde4b inhibitors
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
CA2580781A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coa-desaturase (scd)
TW200621232A (en) 2004-09-21 2006-07-01 Synta Pharmaceuticals Corp Compounds for inflammation and immune-related uses
FR2877015B1 (fr) 2004-10-21 2007-10-26 Commissariat Energie Atomique Revetement nanostructure et procede de revetement.
DE102004054634A1 (de) * 2004-11-12 2006-05-18 Schwarz Pharma Ag Azaindolcarboxamide
US20090074775A1 (en) 2004-12-22 2009-03-19 David Michael Holtzman Use Of Anti-AB Antibody To Treat Traumatic Brain Injury
EP1849465A4 (en) 2005-02-18 2008-12-24 Takeda Pharmaceutical AGENT FOR CONTROLLING THE FUNCTION OF THE GPR34 RECEPTOR
GB0503955D0 (en) 2005-02-25 2005-04-06 Glaxo Group Ltd Novel compounds
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
ATE493413T1 (de) 2005-05-12 2011-01-15 Pfizer Wasserfreie kristalline formen von n-ä1,2- ethoxyethyl)-5-(n-ethyl-n-methylaminoü-7-(4- methylpyridin-2-yl-aminoü-1h-pyrazoloä4,3-
WO2006126083A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors
WO2006126082A2 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
WO2006126081A2 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors
JP2008543923A (ja) 2005-06-22 2008-12-04 ファイザー・プロダクツ・インク ヒスタミン−３受容体アンタゴニスト
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
WO2007052124A1 (en) 2005-11-04 2007-05-10 Pfizer Limited Tetrahydronaphthyridine derivative
WO2007063385A2 (en) 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
WO2007069053A1 (en) 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
WO2007088462A1 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Spirochromane antagonists of the h-3 receptor
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
US20090163482A1 (en) 2006-03-13 2009-06-25 Mchardy Stanton Furst Tetralines antagonists of the h-3 receptor
GB0605462D0 (en) 2006-03-17 2006-04-26 Glaxo Group Ltd Novel compounds
MX2008012456A (es) 2006-04-21 2008-10-10 Pfizer Prod Inc Piridin[3,4-b]pirazinonas.
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
US20080090834A1 (en) 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
US8138205B2 (en) 2006-07-07 2012-03-20 Kalypsys, Inc. Heteroarylalkoxy-substituted quinolone inhibitors of PDE4
US20090291950A1 (en) 2006-07-07 2009-11-26 Kalypsys, Inc. Bicyclic heteroaryl inhibitors of pde4
DE602007011773D1 (de) 2006-08-04 2011-02-17 Merz Pharma Gmbh & Co Kgaa Substituierte pyrazolopyrimidine, ein verfahren zu ihrer herstellung und ihre verwendung als medizin
EP1900739A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Diazolodiazine derivatives as kinase inhibitors
WO2008033739A2 (en) * 2006-09-12 2008-03-20 Neurogen Corporation Benzimidazole carboxamide derivatives
WO2008045664A2 (en) 2006-10-06 2008-04-17 Kalypsys, Inc. Heterocyclic pde4 inhibitors as antiinflammatory agents
US20100105729A1 (en) 2006-10-06 2010-04-29 Kalypsys, Inc. Aryl-substituted heterocyclic pde4 inhibitors as anti-inflammatory agents
US20080102475A1 (en) 2006-10-13 2008-05-01 Zhengyan Kan Alternatively spliced isoform of phosphodiesterase 4B (PDE4B)
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
WO2008056176A1 (en) 2006-11-10 2008-05-15 Scottish Biomedical Limited Pyrazolopyrimidines as phosphodiesterase inhibitors
JP4585610B2 (ja) 2007-01-22 2010-11-24 ファイザー・プロダクツ・インク 治療用化合物のトシル酸塩およびその医薬組成物
NZ582056A (en) 2007-08-10 2012-08-31 Lundbeck & Co As H Bicyclic heteroaryl compounds for treating conditions related to p2x7 receptor activation
MX2010001650A (es) 2007-08-10 2010-08-02 Glaxosmithkline Llc Entidades quimicas biciclicas que contienen nitrogeno para el tratamiento de infecciones virales.
EP2085398A1 (en) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
WO2009108551A2 (en) 2008-02-25 2009-09-03 H. Lundbeck A/S Heteroaryl amide analogues
GB2461702A (en) 2008-07-08 2010-01-13 Dyson Technology Ltd Hand drying apparatus
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
JP2012503623A (ja) 2008-09-24 2012-02-09 ビーエーエスエフ ソシエタス・ヨーロピア 無脊椎動物系害虫防除用ピラゾール化合物
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
EP2408446B1 (en) 2009-03-20 2019-09-11 HG&H Pharmaceuticals (Pty) Limited Use of pharmaceutical compositions containing mesembrenone
CA2778949C (en) 2009-10-30 2018-02-27 Janssen Pharmaceutica Nv Imidazo[1,2-b]pyridazine derivatives and their use as pde10 inhibitors
AU2010323209A1 (en) 2009-11-25 2012-06-14 Merz Pharma Gmbh & Co. Kgaa Crystalline forms of substituted pyrazolopyrimidines
AR079451A1 (es) 2009-12-18 2012-01-25 Nycomed Gmbh Compuestos 3,4,4a,10b-tetrahidro-1h-tiopirano[4,3-c]isoquinolina
US8450354B2 (en) 2010-03-23 2013-05-28 High Point Pharmaceuticals, Llc Substituted imidazo[1,2-b]pyridazine derivatives, pharmaceutical compositions, and methods of use as β-secretase inhibitors
AR081377A1 (es) 2010-05-10 2012-08-29 Gilead Sciences Inc Compuestos de pirazolopiridina bifuncionales
AR081026A1 (es) 2010-05-10 2012-05-30 Gilead Sciences Inc Analogos de quinolina y su uso en el tratamiento de enfermedades respiratorias
WO2012067822A1 (en) 2010-11-16 2012-05-24 Abbott Laboratories Pyrazolo [1, 5 -a] pyrimidin potassium channel modulators
US9096605B2 (en) 2011-08-24 2015-08-04 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as PI3 kinase inhibitors
PE20151332A1 (es) * 2013-02-19 2015-09-20 Pfizer Compuestos de azabencimidazol
WO2014200882A1 (en) 2013-06-11 2014-12-18 Janssen Pharmaceutica Nv PDE10a INHIBITORS FOR THE TREATMENT OF TYPE II DIABETES
GB201321734D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
EP3119347B1 (en) 2014-03-21 2023-06-07 Align Technology, Inc. Segmented orthodontic appliance with elastics
JP6713982B2 (ja) 2014-07-24 2020-06-24 ファイザー・インク ピラゾロピリミジン化合物
KR102061952B1 (ko) 2014-08-06 2020-01-02 화이자 인코포레이티드 이미다조피리다진 화합물

Also Published As

Publication number Publication date
CA2900302C (en) 2018-07-03
AR094702A1 (es) 2015-08-19
TN2015000347A1 (fr) 2017-01-03
IL240672A0 (en) 2015-10-29
CR20150425A (es) 2015-10-20
US20150322065A1 (en) 2015-11-12
ECSP15035278A (es) 2015-11-30
EA201591360A1 (ru) 2016-03-31
JP6505023B2 (ja) 2019-04-24
JP2016507581A (ja) 2016-03-10
MD20150071A2 (ro) 2016-02-29
AP2015008663A0 (en) 2015-08-31
US9120788B2 (en) 2015-09-01
PH12015501755A1 (en) 2015-11-09
CU20150082A7 (es) 2016-02-29
PE20151332A1 (es) 2015-09-20
CA2900302A1 (en) 2014-08-28
CN105121439A (zh) 2015-12-02
EP2958915A1 (en) 2015-12-30
AU2014220351A1 (en) 2015-08-13
MA38333A1 (fr) 2017-02-28
DOP2015000201A (es) 2016-02-15
TW201443048A (zh) 2014-11-16
KR20150119370A (ko) 2015-10-23
NI201500112A (es) 2015-10-19
CL2015002222A1 (es) 2016-01-22
US20140235612A1 (en) 2014-08-21
ES2638850T3 (es) 2017-10-24
WO2014128585A1 (en) 2014-08-28
MX2015010714A (es) 2016-06-14
SG11201505878UA (en) 2015-09-29
BR112015019276A2 (pt) 2017-07-18
JP2019069966A (ja) 2019-05-09
HK1217945A1 (zh) 2017-01-27
US9815832B2 (en) 2017-11-14
EP2958915B1 (en) 2017-07-05

Similar Documents

Publication Publication Date Title
UY35333A (es) Compuestos de azabencimidazol
SV2017005472A (es) Compuestos de triazolopirimidina y usos de los mismos
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
ECSP16076566A (es) Compuestos de heteroarilo o arilo biciclicos fusionados y su aplicación a inhibidores de irak4
CO7400871A2 (es) Compuestos de piridilo sustituidos con heteroarilo útiles como moduladores de cinasa
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
CR20140301A (es) Derivados de betulina
EA201590321A1 (ru) Дейтерированный барицитиниб
CR20210079A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
PE20160862A1 (es) Polimorfo de los inhibidores de la syk
CR20150470A (es) Derivados de triazolona de piridinilo y piridinilo fusionado
EA201690020A1 (ru) Применение производных пиразолопиридина для лечения рака мочевого пузыря
EA201590951A1 (ru) Дигидропиразольные модуляторы gpr40
EA201690894A1 (ru) Феноксиэтилы
UY35143A (es) Derivados de dihidropirazol como moduladores del receptor acoplado a la proteína gpr40 g
EA201590949A1 (ru) Дигидропиразольные модуляторы gpr40
AR095097A1 (es) Compuestos de fenoxietoxi
CU20160003A7 (es) Pirazololpiridinaminas sustituidas
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
CO7141429A2 (es) Nuevos compuestos de pirazol
PH12018500903A1 (en) Pyranodipyridine compound
CU20150006A7 (es) Derivados de (piperidin-4-il)piperazina-1-carboxamida/carboxilato útiles como antagonistas del receptor -h3
CR20150325A (es) Compuestos trcíclicos para inhibir el canal cftr
MX2015008829A (es) Momelotinib deuterado.
CO2019001644A2 (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211105